Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well ...
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2025 Earnings Call Transcript March 12, 2026 Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.31, expectations were $-0.358.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results